Icon Bioscience received FDA approval for Dexycu, a drug designed to treat inflammation after cataract surgery. Here are five notes:
1. Dexycu is applied as a single, post-surgery injection.
2. The drug uses Icon Bioscience's extended-release drug-dispensing technology to inject dexamethasone into the eye's posterior chamber.
3. Typical treatment for inflammation after cataract surgery involves self-administering medicated eye drops several times daily for several weeks.
4. More than 4 million cataract surgeries are performed annually in the U.S., on a largely elderly population.
5. "As Icon steps across the threshold from R&D to an approved product, we look forward to announcing our plans to bring Dexycu into the marketplace," said Icon Bioscience President and CEO David Tierney, MD.